



TITLE: COMPOUNDS AND METHODS TO ENHANCE RAAV TRANSDUCTION
 INVENTOR NAME: John F. Engelhardt et al.
 SERIAL NO.: 10/815,262

1/35




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D

5/35




FIG. 1E




FIG. 2

7/35




FIG. 3

8/35




FIG. 4A




FIG. 4B

9/35




FIG. 4C




FIG. 4D

10/35




FIG. 4E

11/35




FIG. 5A




FIG. 5B

12/35




FIG. 6A




FIG. 6B




FIG. 6C

13/35




FIG. 7A

14/35




FIG. 7B

15/35




FIG. 7C

16/35




FIG. 8A

17/35




FIG. 8B

18/35




FIG. 8C




FIG. 9A

20/35




FIG. 9B

21/35




FIG. 9C




FIG. 9D

23/35




FIG. 10A




FIG. 10B

24/35




FIG. 11A




FIG. 11B

25/35




FIG. 11C




FIG. 11D




FIG. 12A




FIG. 12B




FIG. 12C

27/35




FIG. 13A




FIG. 13B

28/35




FIG. 14A




FIG. 14B

29/35




FIG. 15A




FIG. 15B

FIG. 15C

30/35





FIG. 16

31/35



NO CHEMICAL




FIG. 17B

LLnL 40 μM



FIG. 17C

DOX 5 μM



FIG. 17D

LLnL 40 μM/DOX 5 μM



FIG. 17E




FIG. 17F

32/35




FIG. 18




FIG. 19

33/35




FIG. 20A

34/35

SAMPLE	AVG RLU/mg	STDEV	FOLD CHANGE
VEHICLE	2.95E+03	9.01E+02	
AAV2 FLAG-LUCIFERASE	1.11E+05	3.77E+04	1.00
MG-132 - 20 μ M	1.43E+06	1.72E+06	12.90
DOXORUBICIN 6 μ g/ML	2.10E+07	4.57E+06	189.36
DOXORUBICIN 3 μ g/ML	6.55E+06	1.15E+05	58.99
DOXORUBICIN 0.6 μ g/ML	2.55E+05	1.30E+05	2.30
DAUNORUBICIN 6 μ g/ML	3.17E+08	1.41E+08	2855.65
DAUNORUBICIN 3 μ g/ML	2.40E+07	2.72E+06	216.42
DAUNORUBICIN 0.6 μ g/ML	4.09E+05	6.41E+04	3.69
ELLENCE 6 μ g/ML	1.06E+08	4.85E+07	952.50
ELLENCE 3 μ g/ML	1.33E+07	2.70E+06	120.13
ELLENCE 0.6 μ g/ML	3.81E+05	1.78E+05	3.43
IDAMYCIN 6 μ g/ML	3.87E+04	2.00E+04	0.35
IDAMYCIN 3 μ g/ML	5.99E+08	1.91E+08	5396.31
IDAMYCIN 0.6 μ g/ML	5.30E+07	1.48E+07	477.76

FIG. 20B

35/35




FIG. 21